SCOPUS 정보 검색 플랫폼

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 7, 2010, Pages 473-475

Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer

(11) Strumberg, D a Schultheis, B a Scheulen, M E b Hilger, R A b Krauss, J b,h Marschner, N c Lordick, F d,i Bach, F e Reuter, D e Edler, L f Mross, K g

a RUHR UNIVERSITY BOCHUM (Germany)

b UNIVERSITY HOSPITAL ESSEN (Germany)

c Onkologische Schwerpunktpraxis Freiburg (Germany)

d TECHNICAL UNIVERSITY OF MUNICH (Germany)

e ONCOSCIENCE AG (Germany)

f GERMAN CANCER RESEARCH CENTER DKFZ (Germany)

g UNIVERSITY OF FREIBURG (Germany)

h UNIVERSITY OF HEIDELBERG (Germany)

i KLINIKUM BRAUNSCHWEIG (Germany)

Author keywords

Advanced disease; Clinical trial; EGFR antibody; Nimotuzumab; Pancreatic cancer

Indexed keywords

GEMCITABINE; NIMOTUZUMAB; OSAG 101; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; BLEEDING; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; GASTROINTESTINAL OBSTRUCTION; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SINGLE DRUG DOSE; SKIN TOXICITY; TREATMENT DURATION;

EID: 77954934935 PISSN: 09461965 EISSN: None Source Type: Journal
DOI: 10.5414/CPP48473 Document Type: Conference Paper

Times cited : (11)

References (8)

1
- 27644573890
- Nimotuzumab: Evidence of clinical benefit without rash
- Allan DG. Nimotuzumab: evidence of clinical benefit without rash. Oncologist. 2005; 10: 760-761.
- (2005) Oncologist , vol.10 , pp. 760-761
- Allan, D.G.¹

2
- 8244254377
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
- Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 2403-2413.
- (1997) J Clin Oncol , vol.15 , pp. 2403-2413
- Burris III, H.A.¹ Moore, M.J.² Andersen, J.³ Green, M.R.⁴ Rothenberg, M.L.⁵ Modiano, M.R.⁶ Cripps, M.C.⁷ Portenoy, R.K.⁸ Storniolo, A.M.⁹ Tarassoff, P.¹⁰ Nelson, R.¹¹ Dorr, F.A.¹² Stephens, C.D.¹³ Von Hoff, D.D.¹⁴

3
- 41349099104
- Cancer statistics, 2008
- Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71-96.
- (2008) CA Cancer J Clin , vol.58 , pp. 71-96
- Jemal, A.¹ Siegel, R.² Ward, E.³

4
- 34247149803
- Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma
- Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, Choi DW, Kang WK, Park K, Park JO. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer. 2007; 109: 1561-1569.
- (2007) Cancer , vol.109 , pp. 1561-1569
- Lee, J.¹ Jang, K.T.² Ki, C.S.³ Lim, T.⁴ Park, Y.S.⁵ Lim, H.Y.⁶ Choi, D.W.⁷ Kang, W.K.⁸ Park, K.⁹ Park, J.O.¹⁰

5
- 74949130000
- Nimotuzumab in pediatric glioma
- Lam C, Bouffet E, Bartels U. Nimotuzumab in pediatric glioma. Future Oncol. 2009; 5: 1349-1361.
- (2009) Future Oncol , vol.5 , pp. 1349-1361
- Lam, C.¹ Bouffet, E.² Bartels, U.³

6
- 1642588228
- Pancreatic cancer
- Li D, Xie K, Wolff R, Abruzzese JL. Pancreatic cancer. Lancet. 2004; 363: 1049-1057.
- (2004) Lancet , vol.363 , pp. 1049-1057
- Li, D.¹ Xie, K.² Wolff, R.³ Abruzzese, J.L.⁴

7
- 2342471392
- Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
- Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139.
- (2004) N Engl J Med , vol.350 , pp. 2129-2139
- Lynch, T.J.¹ Bell, D.W.² Sordella, R.³ Gurubhagavatula, S.⁴ Okimoto, R.A.⁵ Brannigan, B.W.⁶ Harris, P.L.⁷ Haserlat, S.M.⁸ Supko, J.G.⁹ Haluska, F.G.¹⁰ Louis, D.N.¹¹ Christiani, D.C.¹² Settleman, J.¹³ Haber, D.A.¹⁴

8
- 34249933404
- Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
- DOI 10.1200/JCO.2006.07.9525
- Moore MJ, Goldstein D, Hamm J, Figer A, He Cht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25: 1960-1966. (Pubitemid 46972777)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.15 , pp. 1960-1966
- Moore, M.J.¹ Goldstein, D.² Hamm, J.³ Figer, A.⁴ Hecht, J.R.⁵ Gallinger, S.⁶ Au, H.J.⁷ Murawa, P.⁸ Walde, D.⁹ Wolff, R.A.¹⁰ Campos, D.¹¹ Lim, R.¹² Ding, K.¹³ Clark, G.¹⁴ Voskoglou-Nomikos, T.¹⁵ Ptasynski, M.¹⁶ Parulekar, W.¹⁷

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.